Cefroxadine
The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity...
Saved in:
Published in | Japanese journal of antibiotics Vol. 35; no. 6; p. 1365 |
---|---|
Main Author | |
Format | Journal Article |
Language | Japanese |
Published |
Japan
01.06.1982
|
Subjects | |
Online Access | Get full text |
ISSN | 0368-2781 |
Cover
Abstract | The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins. |
---|---|
AbstractList | The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins.The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins. The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against E. coli and Klebsiella. Cefroxadine was also proved to have stronger bactericidal or bacteriolytic effect than CEX and have better affinity with penicillin binding proteins. In clinical trials, an efficacy rate of 82.7% was achieved in a total of 2,009 cases of various infections analyzed. Cefroxadine displayed particularly good clinical and bacteriological effects for the infections of skin, soft tissues, respiratory tract and urinary tract. The rate of bacteria eradication in a total of 1,410 cases was 81.6%, showing good results against the bacteria such as S. aureus (83.9%, 167/199), E. coli (89.0%, 528/593), Klebsiella (78.0%, 78/100) and P. mirabilis (80.0%, 36/45). As for side effects, their incidence was a low of only 2.3%, the main ones being eruption and gastrointestinal symptoms just as recognized in conventional cephalosporins, and none of them was serious. Abnormal laboratory test values were only increases in eosinophil, S-GOT, S-GPT and Al-P values, and their incidence was low. From these findings, we may say that the drug is an effective, safe, and useful antibiotic among all other orally administered cephalosporins. |
Author | Mashimo, K |
Author_xml | – sequence: 1 givenname: K surname: Mashimo fullname: Mashimo, K |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/6752462$$D View this record in MEDLINE/PubMed |
BookMark | eNotjrtqxDAQRVVs2Gyc_YS06Qx6zUgqg8kLFtJsb0byCBz82FgxJH-fhbg6zTmXeyd20zzxThykQV9r59WtOJbSRym11yoE2Is9OtAW9UFUDedl_qGun_he3GQaCh83VuL88nxu3urTx-t783SqP5XUusaOzLVHUt4Hw1qnHMAlC8hkbHIMwCEwUOgYM6jobUaKCsjbFJ2pxOP_7GWZv1Yu3-3Yl8TDQBPPa2mdVShDsFfxYRPXOHLXXpZ-pOW33c6bP_edP4Q |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 6752462 |
Genre | Clinical Trial Journal Article Review |
GroupedDBID | .55 3O- 53G 5GY 7.U 8GM ALMA_UNASSIGNED_HOLDINGS CGR CUY CVF ECM EIF F5P JSF JSH KQ8 NPM OK1 RJT RZJ SJN TKC X7J X7M ZJWQK ZXP 7X8 |
ID | FETCH-LOGICAL-j1022-6da36756a18893e22cf957c456ea34c7e55e99e5a9de6f51b84f6ab15a84cb73 |
ISSN | 0368-2781 |
IngestDate | Fri Jul 11 09:53:53 EDT 2025 Tue Aug 05 11:35:05 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Language | Japanese |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-j1022-6da36756a18893e22cf957c456ea34c7e55e99e5a9de6f51b84f6ab15a84cb73 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 ObjectType-Review-3 content type line 23 |
PMID | 6752462 |
PQID | 74160994 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_74160994 pubmed_primary_6752462 |
PublicationCentury | 1900 |
PublicationDate | 1982-Jun 19820601 |
PublicationDateYYYYMMDD | 1982-06-01 |
PublicationDate_xml | – month: 06 year: 1982 text: 1982-Jun |
PublicationDecade | 1980 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan |
PublicationTitle | Japanese journal of antibiotics |
PublicationTitleAlternate | Jpn J Antibiot |
PublicationYear | 1982 |
SSID | ssib002821995 ssib058493060 ssj0000884033 |
Score | 1.3053411 |
SecondaryResourceType | review_article |
Snippet | The antibacterial spectrum of cefroxadine was as wide as that of CEX, and its antibacterial effect was as strong as that of CEX or even 2-fold stronger against... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 1365 |
SubjectTerms | Adolescent Adult Aged Animals Bacteria - drug effects Bacterial Infections - drug therapy Bacterial Infections - microbiology Cephalosporins - therapeutic use Cephradine - adverse effects Cephradine - analogs & derivatives Cephradine - metabolism Cephradine - pharmacology Cephradine - therapeutic use Child Child, Preschool Clinical Trials as Topic Drug Resistance, Microbial Female Humans Male Mice Middle Aged Pregnancy Rabbits Rats |
Title | Cefroxadine |
URI | https://www.ncbi.nlm.nih.gov/pubmed/6752462 https://www.proquest.com/docview/74160994 |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library issn: 0368-2781 databaseCode: KQ8 dateStart: 19680101 customDbUrl: isFulltext: true dateEnd: 20081231 titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html omitProxy: true ssIdentifier: ssj0000884033 providerName: Colorado Alliance of Research Libraries |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba8IwFA7Tp-1h7CZz1z4Mn-ywadKmj0MUGeocVPCtJG0KCrNOK8z9-p30PtjY5SW0gYbmfO3Jd5JzQeiOwapHmOA64T7VSQiNwD7WJRWMisCkEqvY4dHYGkzJ44zOyoJMSXRJLO799y_jSv6DKvQBripK9g_IFoNCB1wDvtACwtD-CuOuDNfRm_KC_-zQAwugKixZTQsBApyLeRRXnNtHqo7SS1TudQZpNByQ4cJJqQh6ApHYadWTXKGl-T8y4KraSbm0lXo_P-seP3n96XDoub2Z21q96qoilzq5zsqT1FANdII67n6uGCYMq9ju_B5YjAO2R6fY3QLdRTpmWps6e8PvKXyylLtH6DDj4NpDKtBjtLfgJ6g1SZN479qaW8akbdpaS5uU6b13p-igIvUz5PZ7bnegZyUl9IUybXUr4CaYSBY3GBA1ibEfOtT2gUVKbhLflpRKx5GUO4G0QmoIRkKLC4NyRnxhmw1UX0ZLeY40k_kiSWdoWQ5MlQDxCZgIBTYDI8TCbqLbfLoe_LHqGAagj7YbT3Fg4OWkiRqpFLxVmljEgzeD8fDFj49eov3ya7hC9Xi9lddAjmJxk-D0Abw9EM0 |
linkProvider | Colorado Alliance of Research Libraries |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cefroxadine&rft.jtitle=Japanese+journal+of+antibiotics&rft.au=Mashimo%2C+K&rft.date=1982-06-01&rft.issn=0368-2781&rft.volume=35&rft.issue=6&rft.spage=1365&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0368-2781&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0368-2781&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0368-2781&client=summon |